On April 10, 2025, the Medicaid and CHIP Payment and Access Commission (MACPAC) held the first day of its April meeting. Some sessions had recommendations that will be voted on tomorrow. Topics in the discussion included the following: Medicaid in Context, Children and Youth with Special Health Care Needs (CYSHCN) Transitions of Care, Timely Access to Home and Community Based Services, Access to Medications for Opioid Use Disorder, Understanding the Program of All-Inclusive Care for the Elderly (PACE) Model, Self-Direction for Home-and-Community-based services, and AI in the Prior Authorization Process.
MEDICAID IN CONTEXT: KEY STATISTICS AND TRENDS AND PAYMENT AND FINANCING
MACPAC staff offered a comprehensive overview of Medicaid, highlighting key statistics and trends across eligibility, demographics, spending, and service coverage. In FY 2024, approximately 88.1 million individuals were enrolled in Medicaid, with a significant portion in the newly eligible adult group, while historically over half were part of child, aged, or disabled categories. Demographically, Medicaid and CHIP enrollees in 2023 were predominantly under 65, female, and from low-income households, with racial diversity including significant Hispanic and Black populations. Medicaid spending nearly doubled from 2013 to 2023, reaching $894.2 billion, with managed care covering the majority of enrollees across all eligibility groups. Medicaid plays a critical role in the health care system, covering nearly a third of the U.S. population and funding a significant portion of national health expenditures. It is also the largest payer of maternity care and long-term services and supports (LTSS), including both home- and community-based services (HCBS) and institutional care.
The second presentation provided a comprehensive overview of the Medicaid financing structure, emphasizing the federal-state partnership. It outlined how the federal government shares costs with states through the Federal Medical Assistance Percentage (FMAP), with variations depending on state income levels. The presentation detailed both federal and non-federal funding sources, such as provider taxes and intergovernmental transfers, and explained the types of payments made to providers, including base, supplemental, and directed payments. It highlighted how these payments affect provider revenues, particularly hospitals, and underscored the complexity of Medicaid financing and its critical role in supporting health care infrastructure, especially in rural areas. The presentation also addressed improper payments and the implications of Medicaid policy on state budgets and provider sustainability.
During the discussion, Commissioners explored various aspects of Medicaid financing and coverage. Commissioner Heidi Allen asked about the FPL group and noted enrollment growth after expansion. Commissioner Angelo Giardino highlighted Medicaid’s importance in rural areas and the reliance of hospitals on Medicaid revenue. Commissioner Doug Brown confirmed spending includes expansion populations, while Commissioner Jami Synder asked about HCBS services like personal care and 24-hour support. Commissioner Michael Nardone requested updated data on dual eligibles, and Commissioner Dennis Heaphy emphasized showing LTSS as a value-based investment and raised concerns about fraud. Commissioner Carolyn Ingram asked about undocumented immigrants—staff noted only emergency coverage is allowed—and flagged tribal rural issues. Commissioners also raised concerns about documentation, outdated data, and payment accuracy.
CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE NEEDS (CYSHCN): TRANSITIONS OF CARE
The next session focused on the challenges and policy recommendations for improving the transition from pediatric to adult care for youth with special health care needs, nearly half of whom are covered by Medicaid. It highlighted gaps in federal guidance, inconsistent state practices, limited data collection, and weak interagency coordination. The presentation included four recommendations for the June 2025 Report to Congress:
- Require all states to develop a transition strategy including individualized care plans
- Direct CMS to issue guidance on existing authorities for funding transition-related services
- Require states to collect and report data on transition service use and outcomes
- Mandate that inter-agency agreements between Medicaid and Title V agencies specify roles in supporting transitions. These efforts aim to enhance continuity of care, improve outcomes, and better support youth and families through a complex healthcare shift.
TIMELY ACCESS HCBS: LEVEL OF CARE DETERMINATIONS AND PERSON-CENTERED SERVICE PLANNING PROCESSES
The following session examined how states manage two essential components of HCBS access for Medicaid beneficiaries: determining eligibility through Level of Care (LOC) assessments and developing individualized Person-Centered Service Plans (PCSPs). LOC determinations assess whether an individual meets the institutional level of care required to qualify for HCBS, and are conducted by various entities, including Medicaid agencies, other state departments, contractors, and managed care organizations. While 32 states have set timelines for conducting assessments (ranging from 2 to 45 days), and 17 states must be timely, culturally appropriate, and led by the individual to the extent possible, with most states requiring development within 30–45 days and annual reviews. States commonly allow professionals such as case managers or nurses to develop the plans, and many have adopted e-signatures to streamline the process.
Insights from interviews with officials in seven states conducted in 2024 revealed a general understanding of federal requirements and widespread agreement on the value of virtual options in certain scenarios, though in-person meetings remain preferred. Many states integrate LOC assessments and PCSP development into the same meeting, which shortens timelines and improves coordination. Officials emphasized that meeting timeframes depend on both staffing and cooperation from healthcare providers. They also noted that while states understand the flexibilities available to them, continued support from CMS—particularly around workforce capacity and streamlining documentation—could further enhance service delivery.
Commissioners discussed the Medicaid eligibility process for HCBS, focusing on the separate timelines for functional and financial eligibility. Commissioner Patti Killingsworth noted the process does not have to be linear, as many states wait to complete steps until eligibility seems likely. Commissioner Michael Nardone questioned delays in financial eligibility and stressed the need for real-world examples to understand what happens during that time. Commissioner Dennis Heaphy highlighted the distinction between eligibility and service planning and emphasized the role of environment in assessing disability. In response to his question, staff explained that assessments are typically conducted by caseworkers, nurses, or contracted professionals, depending on the state.
ACCESS TO MOUD IN MEDICAID
The next presentation provided an overview of Medicaid’s role in improving access to effective treatments like methadone, buprenorphine, and naltrexone. While coverage has expanded due to policy changes— such as telehealth flexibilities and the removal of prescribing restrictions—utilization remains inconsistent across states and demographic groups, with younger adults and non-White beneficiaries less likely to receive treatment. One-third of U.S. counties lack Medicaid-serving MOUD providers, and stigma, limited provider capacity, and utilization management strategies like prior authorization and dosage caps continue to present major barriers.
During the discussion, commissioners raised several issues for future exploration. Commissioner Jennifer Gerstorff emphasized the need to frame OUD as a chronic medical condition rather than a personal weakness and expressed interest in longitudinal studies on treatment success by MOUD type. Commissioner Doug Brown flagged data gaps on extended-release products and physician reimbursement concerns that may limit their use. Commissioners Carolyn Ingram and John McCarthy questioned why Medicaid spending and payment rates for MOUD were not included and suggested examining these in the future. Commissioner Sonja Bjork requested more analysis of access in rural areas, while Commissioner Michael Nardone asked for a deeper dive into state-level variation and whether payment rates play a role. Commissioner Gerstorff also asked whether the report could explore cost savings from expanded access. Staff noted these are important considerations for future MACPAC work.
UNDERSTANDING THE PACE MODEL
The next session reviewed how PACE delivers integrated Medicare and Medicaid services. As of March 2025, over 82,000 people were enrolled across 33 states and D.C., with most being dually eligible. Enrollment is often delayed by lengthy eligibility and application processes, and services are coordinated through interdisciplinary teams at PACE centers. While PACE offers comprehensive benefits, some advocates noted limited home-based services. Oversight involves both federal and state audits and reporting. In FY 2023, Medicaid spent $3.9 billion on PACE, with states setting payment rates as a percentage of expected costs outside the program. MACPAC staff will continue to analyze the model and seek commissioner input for future work.
During the discussion, Commissioners shared mixed perspectives on the PACE model’s value and potential for expansion. Commissioner Patti Killingsworth praised its integrated approach to care but raised concerns about cost-effectiveness, noting the small enrollment of 82,000 and high per-person spending of $48,000. She questioned whether the program’s success was due to administrative f lexibility rather than broader applicability. Commissioner Dennis Heaphy asked what makes the PACE population unique and expressed concern about possible “cherry-picking” or forced transitions to nursing homes. Commissioner Michael Nardone emphasized the strong services for dual eligibles and suggested exploring trends in Medicaid-only PACE participants, including their age and Medicare eligibility status.
Commissioner Carolyn Ingram raised concerns about conflict of interest in the eligibility determination process, where the provider decides who is safe to live in the community, and noted a lack of federal quality standards. She also questioned how rates are set and called for recommendations that address integrated care requirements. Commissioner Heidi Allen pushed back, arguing that while PACE is not for everyone, it is a successful model worth scaling, and comparisons to other programs—like hospital readmission rates—may not be fair. Overall, Commissioners agreed further exploration is needed around cost, accountability, and future recommendations.
SELF-DIRECTION FOR MEDICAID HCBS
The final session of the day was presented by Sanmi Koyejo, PhD, Associate Professor, Stanford University Department of Computer Science and Principal Investigator, Stanford Trustworthy AI Research, Heather McComas, PharmD, Director of Administrative Simplification Initiatives, American Medical Association, and Wayne Turner, JD, Senior Attorney, National Health Law Program. They explored the promises and risks of using AI in Medicaid, particularly around prior authorization and care management. Ms. McComas emphasized that while AI will not fix prior authorization, it could reduce paperwork and clinician burden if applied properly—but warned of risks like treatment abandonment, impersonal care, and biased algorithms. Mr. Turner and Dr. Koyejo echoed concerns that AI, if built on biased or flawed data, could worsen access by wrongly denying care, especially for people with chronic conditions. They stressed the importance of transparency, testing, and ensuring individuals are treated with personalized consideration.
They also highlighted the regulatory challenges, especially with third-party entities using opaque AI tools. Ms. McComas noted cybersecurity and HIPAA concerns, particularly with smaller providers and underrepresented patient groups. Mr. Turner and Dr. Koyejo discussed potential Medicaid-specific uses, such as determining hours of private duty nursing or automating simpler protocols. During the broader Commission conversation, members raised questions about best practices for reducing denial rates, ensuring equitable outcomes, and how AI could trigger external reviews if denial thresholds are exceeded. There were also concerns about AI access in rural areas, the skillsets policymakers need, and the need for rules that ensure human oversight in clinical decisions. Overall, the group emphasized balancing innovation with transparency, equity, and patient-centered care.